Currently out of the existing stock ratings of Judah Frommer, 126 are a BUY (72.83%), 45 are a HOLD (26.01%), 2 are a SELL (1.16%).

Judah Frommer

Work Performance Price Targets & Ratings Chart

Analyst Judah Frommer, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 54.21% that have a potential upside of 29.97% achieved within 195 days.

Judah Frommer’s has documented 319 price targets and ratings displayed on 30 stocks. The coverage is on Consumer Defensive, Consumer Cyclical, Healthcare sectors.

Most recent stock forecast was given on FIVE, Five Below at 17-Jul-2024.

Wall Street Analyst Judah Frommer

Analyst best performing recommendations are on SRPT (SAREPTA THERAPEUTICS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 5/15/2023. The price target of $151 was fulfilled within 1 day with a profit of $6.19 (3.94%) receiving and performance score of 39.38.

Average potential price target upside

of $24.96 (97.91%) on INSM (INSMED).
of $17.22 (29.65%) on SYY (SYSCO).
of $16.62 (122.71%) on RNA (AVIDITY BIOSCIENCES ).

DLTR Dollar Tree FIVE Five Below JSPR Jasper Therapeutics KR Kroger Company OLLI Ollie's Bargain Outlet Hldg SYY Sysco USFD US Foods Holding Corp SFM Sprouts Farmers Market LLC ATAI ATAI Life Sciences BV CRTX Cortexyme EFTR Effector Therapeutics ESPR Esperion Therapeutics FLXN Flexion Therapeutics FULC Fulcrum Therapeutics INBX Inhibrx PEAR Pear Therapeutics PTCT PTC Therapeutics ABOS Acumen Pharmaceuticals RNA Avidity Biosciences DG Dollar General IKNA Ikena Oncology PFGC Performance Food Group Co SRPT Sarepta Therapeutics STOK Stoke Therapeutics BJ BJs Wholesale Club Holdings AKLI Akili CADL Candel Therapeutics INSM Insmed QURE Uniqure NV GLPG Galapagos NV ADR

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

John Heinbockel (GUGGENHEIM)